Short answer
SELLAS Life Sciences Group, Inc. (SLS) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $0 with net income of −$10M.
Q3 2026 key financials · XBRL
- Revenue
- $0
- Net income
- −$10M
- −48.6% YoY · −5.1% QoQ
- EPS (diluted)
- −$0.05
- +28.6% YoY · +0.0% QoQ
Source: XBRL data from the SELLAS Life Sciences Group, Inc. (SLS) Q3 2026 10-Q on SEC EDGAR. USD.
SELLAS Life Sciences Group, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0 from product sales in nine months ended September 30, 2026, unchanged YoY
- Net loss $10.1M vs $6.8M YoY, operating loss $11.3M vs $7.1M
- SLS009 strongest clinical results: 34% ORR all doses, 54% monocytic AML at selected dose
- Cash and equivalents $134.7M plus restricted cash $0.1M, warrant exercises generated $85.1M
- Outlook: cash sufficient for at least twelve months, Phase 2 enrollment ongoing, REGAL topline results expected November 2026
Risk Factors
- No material changes disclosed from the 2025 Annual Report
- Clinical-stage biotechnology risk: Additional unknown risks could materially harm business, financial condition, results, or stock price
- Forward-looking statement risk: Projections remain subject to uncertainties incorporated by reference
- Stock-price risk: Undisclosed or currently immaterial risks could adversely affect valuation
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other SELLAS Life Sciences Group, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.